Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doxorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 1.00 |
| ▸ | THRB | P10828 | 8/20 | 1.00 |
| ▸ | BLM | P54132 | 8/20 | 1.00 |
| ▸ | RECQL | P46063 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | S100A4 | P26447 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | STAT6 | P42226 | 4/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epirubicin SCHEMBL9335136 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6251124 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL3242 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL571906 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL317302 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL6423994 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL57097 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669731 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Epirubicin SCHEMBL21669733 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL5324652 | 1.00 | MEN1 (1.00) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 850 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478586-B2 | Small molecular drug-loaded polymer vesicle, preparation method therefor and use thereof | SOOCHOW UNIVERSITY (CN) | 2025-11-25 | — | — | US | claimed |
| US-20240099977-A1 | SMALL MOLECULAR DRUG-LOADED POLYMER VESICLE, PREPARATION METHOD THEREFOR AND USE THEREOF | SOOCHOW UNIVERSITY (CN) | 2024-03-28 | — | — | US | claimed |
| WO-2023208094-A1 | HOLLOW EMBOLIC MICROSPHERE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 浙江理工大学 | 2023-11-02 | — | — | WO | claimed |
| CN-115779096-A | Synthetic method of porous calcium carbonate microspheres for drug loading | 贺州学院 | 2023-03-14 | — | — | CN | claimed |
| CN-111333786-B | Preparation method of acid-sensitive adriamycin prodrug based on zwitterion and folic acid targeting | 苏州大学 | 2023-01-06 | — | — | CN | claimed |
| CN-115554267-A | Pectin-based ultraviolet light response type nano carrier and preparation method thereof | 南京医科大学康达学院 | 2023-01-03 | — | — | CN | claimed |
| CN-115501378-A | Modified polyvinyl alcohol embolism microsphere and preparation method thereof | 江南大学 | 2022-12-23 | — | — | CN | claimed |
| CN-115429744-A | Near-infrared light responsive injectable temperature-sensitive hydrogel and preparation method and application thereof | 中国科学院上海硅酸盐研究所 | 2022-12-06 | — | — | CN | claimed |
| CN-114209871-B | Preparation method of chemotherapy drug nanoparticle-iodized oil ultrastable homogeneous suppository | 厦门大学 | 2022-12-06 | — | — | CN | claimed |
| CN-112516310-B | Preparation method and application of nano prodrug with response to tumor acid environment | 武汉理工大学 | 2022-11-29 | — | — | CN | claimed |
| US-20080145399-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | COOK MEDICAL TECHNOLOGIES LLC | 2008-06-19 | — | — | US | claimed |
| US-20080145398-A1 | coronary stent has a multilayer coatings for controlled release of immunosuppressive agent active materials, including a porous cover layer | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2008-06-19 | — | — | US | claimed |
| US-20030036794-A1 | Coated implantable medical device | COOK INCORPORATED | 2003-02-20 | — | — | US | claimed |
| EP-0457250-B1 | Novel bifunctional linking compounds, conjugates and methods for their production | BRISTOL MYERS SQUIBB CO (US) | 1999-07-14 | — | — | EP | claimed |
| EP-0525073-B1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | DU PONT (US) | 1994-05-25 | — | — | EP | claimed |
| EP-0525073-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. | DU PONT (US) | 1993-02-03 | — | — | EP | claimed |
| WO-1991015954-A1 | ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-10-31 | — | — | WO | claimed |
| EP-0228546-B1 | METHOD FOR THE PREPARATION OF 4'-0-TETRAHYDROPYRANYLADRIAMYCIN B | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1989-09-13 | — | — | EP | claimed |
| US-4818818-A | Method for the preparation of 4'-0-tetrahydropyranyladriamycin b | ZAIDANHOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) | 1989-04-04 | — | — | US | claimed |
| EP-0228546-A2 | Method for the preparation of 4'-0-tetrahydropyranyladriamycin b | Zaidanhojin Biseibutsu Kagaku Kenkyukai (JP) | 1987-07-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099977-A1 | SMALL MOLECULAR DRUG-LOADED POLYMER VESICLE, PREPARATION METHOD THEREFOR AND USE THEREOF | CHMP4B, VCL, VPS51 | TOP2A 3126/4885MEN1 159/4885KMT2A 1957/4885 |
| US-12478586-B2 | Small molecular drug-loaded polymer vesicle, preparation method therefor and use thereof | CHMP4B, VCL, VPS51 | TOP2A 3126/4885MEN1 159/4885KMT2A 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.